Condition
Broader IBD news covering Crohn's disease, ulcerative colitis, research, treatments, monitoring, and patient care.
Page 16 of 88 · 4177 articles
This study explores a novel, non-invasive way to block IL-23 — an important inflammatory driver in IBD — by orally delivering small IL-23 inhibitors using engineered Lactococcus lactis in mouse colitis models.
Cure8 could only read part of this source from Annals of Pediatric Endocrinology & Metabolism, so this card uses cautious topic tags instead of a full summary. It is tagged for Inflammatory bowel disease and Pediatrics...
The study suggests adding a structured 16-week exclusive enteral nutrition plan to ustekinumab treatment may improve short- and medium-term clinical and endoscopic outcomes for adults with moderate-to-severe Crohn’s...
Links between GWAS risk loci and the specific cell types where those loci may act can focus laboratory experiments and eventually help identify causal genes or pathways relevant to Crohn’s disease.
Based on the title and source metadata, this appears to be a case report related to Ulcerative colitis, Inflammatory bowel disease, and Tests and monitoring. The original article is from Cureus.
This review explains how new drug classes and mechanism-focused strategies may change how IBD is treated, which could affect choices for patients who have not responded to existing therapies and inform discussions about...
Many people with IBD use over-the-counter pain relievers without realizing they can irritate the gut. This article explains when ibuprofen or naproxen might raise risks for people with Crohn’s disease or ulcerative...
Based on the title and source metadata, this appears to be a clinical study related to Ulcerative colitis, Inflammatory bowel disease, and Microbiome. The original article is from AMB Express.
This mouse study identifies a plant polysaccharide that reduced colitis-related inflammation and improved colon histology, suggesting potential microbiome and lipid‑metabolism mechanisms that could inform future research...
The review identifies a novel molecular mechanism (S-palmitoylation) that may drive barrier dysfunction and intestinal inflammation in IBD, suggesting new non-immunosuppressive therapeutic targets that could eventually...
The review suggests NETs are elevated in IBD and that reducing NETs activity helped in animal models—so NETs could be a future therapeutic target and a biomarker of disease severity.
The review proposes S100B as a molecular link connecting enteric glial activation, intestinal barrier dysfunction, and liver/brain inflammation. If confirmed, this could help explain symptom overlap between gut and...
Based on the title and source metadata, this appears to be a basic science related to Ulcerative colitis, Inflammatory bowel disease, and Research and clinical trials. The original article is from Pharmaceutical...
GLP-1 and dual GIP/GLP-1 agonists are being studied as treatments that could help people with IBD who also have obesity or metabolic problems by reducing weight and inflammation without clearly worsening IBD. This could...
The study presents a preclinical strategy to concentrate an existing antihistamine drug in the colon and reduce systemic exposure, which could improve local efficacy and safety for IBD treatment if later validated in...
The review compiles trial and real-world safety data for upadacitinib in IBD and highlights monitoring needs and infection risks (notably herpes zoster), which are directly relevant when choosing or managing JAK...
The work aims to improve colon-targeted delivery of an aminosalicylate (balsalazide) to boost local drug levels and protect the drug from gastric degradation—potentially relevant to people with ulcerative colitis looking...
Based on the title and source metadata, this appears to be a case report related to Inflammatory bowel disease and Complications. The original article is from Journal of investigational allergology & clinical immunology.
If you or someone you care for uses or may use VELSIPITY (etrasimod) for ulcerative colitis, local manufacturing and priority review in China could improve drug supply, availability, and potentially lower costs. The...
Researchers report that a polysaccharide from Radix Hedysari reduced inflammation, improved barrier proteins, and shifted gut bacteria in a mouse model of ulcerative colitis — suggesting a potential preventive candidate...
Early, easily available blood markers that predict mucosal healing could help clinicians decide sooner whether a new or intensified therapy is working, potentially reducing prolonged ineffective treatment and guiding...
Researchers are testing a new swallowable thermal capsule that could eventually help detect temperature changes from GI inflammation. For people with Crohn’s disease or IBD, a safe, noninvasive way to sense inflammatory...
A minimally invasive probe that measures intestinal potential difference in real time could provide a localized, objective way to study gut barrier function—an important feature in Crohn’s disease and other IBDs....
Stigma and avoidance can harm social and work functioning for people with IBD. Knowing which factors increase avoidance (visible symptoms, prolonged contact, absence of a diagnosis label) can help patients and clinicians...
Researchers are developing oral delivery methods to make promising anti‑inflammatory compounds more effective. If such platforms translate to humans, they could expand treatment options for UC by improving absorption of...
Based on the title and source metadata, this appears to be a patient education related to Ulcerative colitis, Inflammatory bowel disease, and Colonoscopy. The original article is from Digestive and liver disease :...
Based on the title and source metadata, this appears to be a clinical study related to Crohn's disease, Inflammatory bowel disease, and Tests and monitoring. The original article is from Gastro hep advances.
EEN is a common treatment in paediatric Crohn's disease. Understanding the burdens and support needs can help families and clinicians plan practical, social, and school-based supports to improve adherence and experience...
Self-esteem, body image, mental health, and sexual satisfaction are linked in women with IBD and can affect quality of life. Addressing these issues in routine care may improve overall wellbeing and adaptation to chronic...
Based on the title and source metadata, this appears to be a basic science related to Ulcerative colitis, Inflammatory bowel disease, and Research and clinical trials. The original article is from Enzyme and Microbial...
This study suggests transgender and gender non-conforming people with IBD may face longer diagnostic delays, higher psychiatric comorbidity, and possibly more hospitalisations or surgery. That could mean gaps in care or...
The paper identifies a specific probiotic strain that reduced colitis signs and improved intestinal barrier function in a mouse model, supporting further preclinical and translational work toward microbiome-based...
The study proposes a machine learning approach to identify SNPs linked to Crohn’s disease risk, which could help researchers prioritize genetic variants for further study and, eventually, contribute to risk prediction or...
Personal stories can show how severe and disruptive Crohn’s symptoms can be, and that diagnosis may take time. The account also reinforces that Crohn’s is chronic and may require ongoing medical treatment plus lifestyle...
A child with Crohn’s disease is helping launch a national Halloween fundraiser that raises money for Children’s Health Ireland services and research; families affected by pediatric IBD may benefit from or want to support...
Cure8 found this source from tipranks.com, but the page could not be read reliably yet. It is tagged for Crohn's disease, Inflammatory bowel disease, and Ontunisertib. Open the original article for the full details.
Positive results and a planned Phase 2b study suggest ontunisertib is progressing in development for fibrostenosing Crohn’s disease — a condition with limited targeted therapies for intestinal fibrosis.
Cure8 found this source from app.dealroom.co, but the page could not be read reliably yet. It is tagged for Crohn's disease, Inflammatory bowel disease, and Ontunisertib. Open the original article for the full details.
Mental-health conditions are more common around the time IBD is diagnosed and can persist for years, so early recognition and coordinated care may improve overall outcomes and quality of life.
People with IBD who have failed multiple advanced therapies are often the most difficult to treat, yet this review shows they are under-represented in clinical trials. That limits direct evidence about how well new...
New biomarkers and cell-type insights could help future diagnostic tools or targeted therapies in UC by pointing to TRP channel–related genes and B/plasma cell involvement.
The study links a common compound in plant foods (oxalate) to intestinal inflammation in IBD, suggesting diet and oxalate metabolism may be modifiable contributors to flares.
The work helps explain why smoking increases Crohn’s risk but seems protective for ulcerative colitis by identifying genetic loci and smoking-dependent gene expression changes that differ between the two diseases. That...
The gut–liver axis links intestinal inflammation to liver disturbances in IBD. This preclinical study suggests a specific oat β‑glucan fraction reduced liver oxidative stress and inflammation in rats with chemically...
Standardised care pathways may reduce hospital admissions and help health systems manage the burden of IBD without worsening patient-reported disease control.
The work links a specific transcriptional regulator (GABPA) to STING-driven interferon and inflammatory responses and shows relevance to IBD and SLE patient samples, pointing to a potential new target for therapies aimed...
Patients with refractory IBD or those not fully responding to single targeted therapies may be interested because ACT aims to control multiple inflammatory pathways and could offer improved symptom and endoscopic...
Cure8 could only read part of this source from PubMed Central, so this card uses cautious topic tags instead of a full summary. It is tagged for Inflammatory bowel disease and Research and clinical trials.
